Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe  by Erlandson, Kristine M. et al.
International Journal of Infectious Diseases 24 (2014) 6–10Relationship of vitamin D insufﬁciency to AIDS-associated Kaposi’s
sarcoma outcomes: retrospective analysis of a prospective clinical trial
in Zimbabwe
Kristine M. Erlandson a,*, Ivy Gudza b, Suzanne Fiorillo a, Buxton Ndemera b,
Robert T. Schooley c, Lovemore Gwanzura d, Margaret Borok b, Thomas B. Campbell a
aDepartment of Medicine, Division of Infectious Diseases, University of Colorado Denver, 12700 E. 19th Avenue, Mail Stop B168, Aurora, CO 80045, USA
bDepartment of Medicine, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
cDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California, USA
dDepartment of Medical Laboratory Sciences, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
A R T I C L E I N F O
Article history:
Received 16 October 2013
Received in revised form 3 February 2014
Accepted 5 February 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
AIDS-KS
Vitamin D insufﬁciency
HIV
S U M M A R Y
Objectives: The prevalence of vitamin D insufﬁciency in Africans with AIDS-associated Kaposi sarcoma
(AIDS-KS) and the role of vitamin D in AIDS-KS progression are unknown. We hypothesized that a high
prevalence of vitamin D deﬁciency would be found in Zimbabweans with AIDS-KS and that low baseline
vitamin D would correlate with progression of AIDS-KS.
Methods: Ninety subjects were enrolled in a prospective pilot study investigation of the effect of
antiretroviral therapy in the treatment of AIDS-KS in Harare, Zimbabwe. Co-formulated abacavir,
lamivudine, and zidovudine was initiated; chemotherapy was provided at the discretion of the provider.
Participants were followed for 96 weeks. 25-Hydroxyvitamin D was measured in stored specimens
collected at study entry. The relationship between vitamin D and clinical response was described by odds
ratio and 95% conﬁdence interval.
Results: Samples were available for 85 participants; 45 (53%) subjects had inadequate (<75 nmol/l) 25-
hydroxyvitamin D. HIV-1 RNA was signiﬁcantly higher among those with insufﬁcient vitamin D (4.7 vs.
4.5 log, p = 0.04). Tumor response, survival, and KS-IRIS were not associated with vitamin D (p  0.3).
Conclusions: Vitamin D insufﬁciency was common among Zimbabweans with AIDS-KS but not
associated with outcomes after initiation of antiretroviral therapy.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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AIDS-associated Kaposi’s sarcoma (AIDS-KS) is the most
common tumor in Zimbabwe.1 Without antiretroviral therapy
(ART), AIDS-KS is associated with more than 85% mortality, due to
progression of KS or complications associated with advanced
AIDS.2With effective ART, the mortality associated with AIDS-KS is
improved, but the response of clinical AIDS-KS lesions is
discouraging, at less than 20%.3
Moderate associations of low vitamin D levels with cancer
progression have been observed in stomach, esophageal, gallbladder,* Corresponding author. Tel.: +1 303 724 4941; fax: +1 303 724 4926.
E-mail address: Kristine.Erlandson@ucdenver.edu (K.M. Erlandson).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).colon, breast, prostate, and pancreatic cancer.4–7 Cancers with the
most sensitive vitamin D effect appear to be those of rapidly
proliferating tissue, speciﬁcally the oral–gastrointestinal tract and
the bone marrow.8 Forms of vitamin D have been shown to inhibit
tumor angiogenesis, and calcitriol both inhibits9–11 and upregulates
vascular endothelial growth factor and angiogenesis in non-KS
tumors.12,13 Little is known about the effect of vitamin D or the
vitamin D receptor on vascular tumors such as KS. In vitro, both the
activated form of vitamin D, 1,25-dihydroxycholecalciferol
(1,25(OH)2D,calcitriol),andavitaminDanaloguehavedemonstrated
inhibition of KS transformed cell lines.14–18 Mice with implanted KS
tumors treated with calcitriol or a vitamin D analogue showed
signiﬁcant slowing of tumor growth.14,17 Of eight male patients with
KS treated with the topical synthetic vitamin D receptor agonist
calcipotriene, 50% had improvement in cutaneous lesions.14ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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with HIV-1 infection in the USA and in European countries.19–22
Persons recently emigrated from Africa to the USA, Europe, or
Australia often have vitamin D insufﬁciency.23–26 Existing data on
vitamin D among persons with or without HIV-1 residing in Sub-
Saharan Africa also suggest a high prevalence of vitamin D
insufﬁciency or deﬁciency.27–32Based on the existing epidemiologi-
cal and in vitro and in vivo data described above, we hypothesized
that a high prevalence of vitamin D deﬁciency would be found in
Zimbabweans with AIDS-KS and that low baseline vitamin D would
be associated with the progression of AIDS-KS.
2. Methods
2.1. Study population
The current study was a retrospective analysis of existing data
and stored specimens from 90 subjects enrolled in a prospective
investigation of the effect of ART in the treatment of AIDS-KS
(Clinicaltrials.gov number NCT00834457) at the Parirenyatwa
Hospital Kaposi Sarcoma Clinic in Harare, Zimbabwe between June
2003 and May 2005.3 The study was reviewed and approved by the
Medical Research Council of Zimbabwe and the Colorado Multiple
Institutional Review Board, and informed consent was obtained
from all participants. All participants had KS conﬁrmed by
histopathological examination. Other entry criteria included age
>18 years, conﬁrmed presence of HIV-1 antibody, hemoglobin
>7.5 g/dl, absolute neutrophil count >750 cells/ml, agreement not
to participate in a conception process during study participation,
ART naı¨ve, no receipt of chemotherapy or radiation therapy 45
days before study entry, and no intention to relocate out of the
Harare area for the duration of study participation. Co-formulated
abacavir, lamivudine, and zidovudine was initiated in all partici-
pants on day 0. Participants were followed for 96 weeks.3
2.2. Clinical and immunological/virological outcomes
The stage of KS was assessed using the criteria of both Krigel et al.
and the AIDS Clinical Trials Group, as described previously.3,33,34
Clinical responsewasdeﬁnedaseither completeorpartial resolution
ofclinicallyapparentKSdiseaseatweek96.Completeresolutionwas
deﬁned as the absence of KS lesions and tumor-related edema for a
minimum of 4 weeks, lasting until the end of the follow-up period.
Partial resolution was deﬁned as 50% improvement in KS lesions
without complete resolution. KS-associated immune reconstitution
inﬂammatory syndrome (KS-IRIS) was deﬁned as any progression of
KS occurring 12 weeks after initiation of ART and was associated
with an increased CD4+ lymphocyte count of at least 50 cells/ml
above the baseline value, before or at the time of documented KS
progression. Virological failure was deﬁned as failure to suppress or
failure to maintain suppression of the plasma HIV-1 RNA level to
<400 copies/ml after week 24.
3,35 Plasma samples obtained at study entry were assayed for
25-hydroxyvitamin D (25(OH)D) with the Liaison immunolumino-
metric direct assay (DiaSorin, Stillwater, MN, USA). Vitamin D
deﬁciency was deﬁned as 25(OH)D 50 nmol/l and insufﬁciency as
>50 nmol/l but <75 nmol/l. Inadequate and adequate 25(OH)D
were deﬁned as <75 nmol/l and 75 nmol/l, respectively.20,36,37
The rainy season was deﬁned as November through April and the
dry season as May through October.
2.3. Data analyses
Continuous variables are reported asthe median andinterquartile
range (IQR) and categorical variables as the frequency and percent-
age. Continuous variables were tested with the Mann–Whitneytest and categorical variables with the Chi-square test or Fisher’s
exact test. The relationship between vitamin D and clinical
response was described by odds ratio (OR) and 95% conﬁdence
interval (95% CI) and tested with a Chi-square or Fisher’s exact
test. Logistic regression models were used to adjust for possible
confounding of HIV-1 viral load and CD4 count in predicting
clinical outcomes. Other analyses were considered exploratory
and were not corrected for multiple comparisons. Statistical
analyses were conducted in SAS v. 9.2 (SAS Institute) and
GraphPad Prism (GraphPad Software Inc.), and assumed a two-
sided signiﬁcance level of 0.05.
3. Results
3.1. Prevalence of vitamin D insufﬁciency and study participant
characteristics
Baseline serum samples were available for 85 of 90 subjects. Of
those with available samples for analysis, the median 25(OH)D was
72.5 nmol/l (IQR 56.3–88.8 nmol/l). Forty-ﬁve (53%) subjects had
inadequate 25(OH)D and 17 (20%) had 25(OH)D insufﬁciency.
Fourteen subjects died, 11 subjects were lost to follow-up prior to
week 96, and 60 subjects completed 96 weeks of observation
(Figure 1). Further characteristics of the study population are
provided in Table 1. Those enrolling during the rainy season had
higher median 25(OH)D levels (78.75 vs. 62.5 nmol/l, p = 0.01).
3.2. Relationship of vitamin D status and clinical outcomes
Twenty-nine subjects were diagnosed with stage 4 KS at study
entry and 71 with T1 disease; the median vitamin D in these
subjects was 66.5 nmol/l (IQR 55.8–88.8) and 73 nmol/l (IQR 58–
90), respectively. The proportion of stage 4 or T1 disease was
similar between the 25(OH)D groups, and 25(OH)D levels were
similar between persons with earlier and later stages of AIDS-KS, as
shown in Table 1 and Table 2, respectively. Sixteen subjects (19%)
had a partial or complete clinical response, 16 (19%) developed KS-
IRIS, 49 (58%) required chemotherapy, and 22 (26%) required
radiation therapy by 96 weeks. Clinical response (OR 0.6, 95% CI
0.2, 1.9; p = 0.4), development of KS-IRIS (OR 0.4, 95% CI 0.2, 1.9; p =
0.4), need for chemotherapy (OR 1.2, 95% CI 0.5, 2.8; p = 0.7), and
need for radiation therapy (OR 0.6, 95% CI 0.2, 1.5; p = 0.2) were
similar between those with inadequate and adequate 25(OH)D.
ORs and signiﬁcance remained unchanged after adjustment for
HIV-1 viral load and CD4 count. The median 25(OH)D was not
signiﬁcantly different between those with or without a clinical
response, KS-IRIS, chemotherapy, or radiation therapy (Table 2).
Baseline 25(OH)D measurements were available for 12 of 14
participants who died during the study. Those who died during the
study had similar 25(OH)D (63 nmol/l, IQR 46–79) as the 60
subjects known to have survived to 96 weeks (69 nmol/l, IQR 55–
85; p = 0.27). The odds of death by 96 weeks was not signiﬁcantly
associated with 25(OH)D (OR 0.5, 95% CI 0.1, 1.9; p = 0.3) and
remained unchanged when adjusting for plasma HIV-1 RNA and
CD4+ lymphocyte count.
3.3. Vitamin D and immunological/virological parameters
25(OH)D insufﬁciency was associated with signiﬁcantly higher
baseline plasma HIV-1 RNA and greater decrease in HIV-1 viral
load with ART initiation (p = 0.04, Table 1). Baseline CD4+ count
and CD4+ cell increase with ART were slightly lower in persons
with vitamin D insufﬁciency, however this did not reach statistical
signiﬁcance (p  0.5). HHV-8 viral load in plasma and PBMC were
similar between the 25(OH)D groups (Table 1).
Figure 1. Flowchart of study participants.
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Few studies have evaluated the prevalence of vitamin D
insufﬁciency in HIV-infected adults living in Sub-Saharan Africa
and no prior published studies have evaluated 25(OH)D insufﬁ-
ciency among Zimbabweans or in persons with KS-AIDS. The
limited in vitro data on vitamin D or vitamin D agonists in KS and in
other vascular tumors have been conﬂicting. Our study provides
the ﬁrst analyses of vitamin D insufﬁciency among HIV-infected
adults in Zimbabwe and is the ﬁrst to investigate relationshipsTable 1
Comparison of demographic and clinical characteristics between persons with insufﬁc
Characteristic Inadequate 25(O
(n = 45)
Demographics
Age, years 38 (33–45) 
Gender, female 14 (31) 
BMI, kg/m2 21.5 (20.0–22.8
Disease stage
Stage 4 KS 23 (51) 
ACTG T1 38 (84) 
Baseline laboratory
Hemoglobin 11 (9.4–11.9) 
CD4+ lymphocyte count 117 (76–208) 
HIV-1 viral load (log) 4.7 (4.3–5.0) 
HHV-8 plasma viral load (log) 2.9 (2.1–3.5) 
HHV-8 PBMC viral load (log) 3.2 (2.4–4.4) 
96 week changeb
Increase in CD4+ lymphocyte count 85 (21–291) 
Decrease in HIV-1 viral load (log) 1.9 (1.3–2.4) 
Decrease in HHV-8 plasma viral load (log) 0.5 (0–1.5) 
Decrease in HHV-8 PBMC viral load (log) 0.9 (0.4–2.3
25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; ACTG T1, AIDS Clinical Trials G
peripheral blood mononuclear cells.
a Median and interquartile range or number and percentage are reported for each v
b Week 96 or last available results.between 25(OH)D insufﬁciency and clinical and immunological/
virological outcomes of persons with KS-AIDS.
The higher baseline HIV-1 RNA observed among subjects with
25(OH)D insufﬁciency is reported in the literature and may reﬂect
the integral role of vitamin D in innate immunity.19,27,38
Unexpectedly, we observed a greater decrease in HIV-1 RNA in
persons with inadequate 25(OH)D and slightly higher baseline
25(OH)D among persons with virological failure. Early in vitro
studies of HIV and vitamin D suggested an increase in HIV-1
replication with 1,25(OH)2D partially mediated by inﬂammatoryient and adequate 25-hydroxyvitamin Da
H)D Adequate 25(OH)D
(n = 40)
p-Value
36 (31–43) 0.4
12 (30) 0.9
) 21.5 (19.0–24.3) 1.0
17 (43) 0.4
33 (83) 0.8
11.3 (10.3–12.6) 0.2
141 (70–222) 0.5
4.5 (3.9–4.9) 0.04
2.8 (1.8–3.4) 0.4
3.5 (2.5–4.1) 0.8
105 (30–202) 0.8
1.3 (0.8–1.9) 0.04
0.4 (0–1.5) 0.8
) 1.0 (0–2.0) 0.9
roup tumor 1 staging; KS, Kaposi sarcoma; HHV-8, human herpes virus 8; PBMC,
ariable.
Table 2
Median 25-hydroxyvitamin D levels (nmol/l) by baseline disease stage and clinical
outcomes
Clinical characteristic Median 25(OH)D IQR p-Value
KS clinical stage 0.8
2 or 3 75 57–91
4 72 56–89
ACTG stage 0.4
0 73 40–85
1 73 58–90
Survival status 0.3
Alive at 96 weeks 69 55–85
Died by 96 weeks 63 46–79
Clinical response 0.7
Partial or complete 64 56–88
No response 73 58–92
Immune response
No KS-IRIS 73 57–89 0.7
Developed KS-IRIS 64 56–88
HIV-1 virological response 66 55–86 0.3
HIV-1 virological failure 83 58–93
Adjunctive therapy
No chemotherapy 66 52–93 0.8
Chemotherapy 73 57–88
No radiation therapy 75 58–90 0.5
Radiation therapy 67 55–86
25(OH)D, 25-hydroxyvitamin D; IQR, interquartile range; KS, Kaposi sarcoma;
ACTG, AIDS Clinical Trials Group; KS-IRIS, Kaposi sarcoma immune reconstitution
inﬂammatory syndrome.
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increased HIV-1 expression. Subsequent studies have largely
suggested a suppressive effect of 25(OH)D and 1,25(OH)2D.
38,43
Alternatively, higher levels of immune activation, inﬂammatory
cytokines, or HIV-1 RNA itself may interfere with conversion of
25(OH)D,44,45 thus our ﬁndings may not accurately represent the
levels of biologically active vitamin D, 1,25(OH)2D. The short half-
life and transient changes in 1,25(OH)2D make this assay much less
useful in determining vitamin D status.37
A potential limitation of our study is that we studied only the
relationship between baseline 25(OH)D and clinical and immuno-
logical/virological outcomes. Our analysis would not have captured
the impact of changes in 25(OH)D associated with ART initiation or
nutritional status that may have occurred during the course of the
study.21 The small sample population and event number may have
limited our power to detect signiﬁcant differences in outcomes (i.e.,
survival, clinical response, receipt of adjunctive therapy, develop-
ment of KS-IRIS). Receipt of chemotherapy or radiation therapy was
affected by availability. Regardless of these limitations, we found
that more than one half of Zimbabweans with KS-AIDS enrolling in
our study had insufﬁcient 25(OH)D. While persons with KS-AIDS
may not be representative of the majority of HIV-infected
Zimbabweans, the mean 25(OH)D level (75.5 nmol/l) of our
population is similar to the weighted mean (84.7 nmol/l) of other
African populations with and without HIV infection.23,24,28–31,46,47
In summary, despite associations between vitamin D deﬁciency
and severe disease, AIDS, and death,22,48 we were unable to
demonstrate improved KS-AIDS outcomes in clinical response,
need for chemotherapy or radiation, development of KS-IRIS,
survival rates, or more favorable immunological response49 to ART
in association with higher levels of vitamin D. Larger studies
should investigate longitudinal associations with vitamin D state
in persons with AIDS-KS and other malignancies prior to routinely
recommending vitamin D replacement.
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